# US 2022/0031864 A1 · Quantitative regulation of a g protein signalling pathway

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031864 A1
- Document ID: US20220031864A1
- Status: Published application
- Kind: A1
- Application number: 17/277,672
- Filed: 2019-09-24
- Published: 2022-02-03
- Earliest claimed: 2018-09-24
- Assignees: The University of Manchester
- Applicants: The University of Manchester
- Inventors: Robert Lucas; Jessica Rodgers
- Web page: https://patentgrep.com/patent/US20220031864A1

## CPC

- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 27/02: Ophthalmic agents
- C07K 14/461: {from fish}
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- G01N 33/5005: {involving human or animal cells (immunoassay G01N33/56966; immunoassays of protozoa G01N33/56905; protozoa in screening assays C12Q1/025)}
- A01K 2227/105: Murine
- A01K 2267/0306: Animal model for genetic diseases
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to methods of regulating G protein activity, and related methods for the treatment of therapeutic conditions, for example retinal degeneration, by transforming a cell with a bistable opsin to activate a G protein, and provide a phototransduction response.

## Claims

### Claim 1

A method of regulating Go protein activation in a cell, wherein the method comprises i) transforming the cell with a vector encoding a bistable opsin, wherein the bistable opsin has an inactive and an active state, and transition in both directions between inactive and active states are driven by light absorption; and wherein the bistable opsin in the inactive state is sensitive to a first wavelength of light for transition to an active state, and the bistable opsin in the active state is sensitive to a second wavelength of light for transition to an inactive state, the first and second wavelengths being different; ii) expressing the bistable opsin in the transformed cell; iii) illuminating the transformed cell expressing the bistable opsin with light comprising the first and/or second wavelength, wherein the ratio of the two wavelengths of light regulates a Go protein activation.

### Claim 2 (depends on 1)

A method according to claim 1 wherein the regulation of the Go protein comprises quantitative regulation.

### Claim 3 (depends on 1, 2)

A method according to any one of claim 1 or 2 wherein the method comprises ON-OFF regulation of the Go protein, by exposing the cell to either light of a first wavelength or light of a second wavelength.

### Claim 4 (depends on 1, 2, 3)

A method according to any one of claims 1 to 3 wherein the method relates to regulation of a Go protein in a retinal cell, further wherein the bistable opsin is lamprey parapinopsin.

### Claim 5 (depends on 1, 2, 3, 4)

A method according to any one of claims 1 to 4 wherein the cell is an inner retinal cell, for example a bipolar cell, for example an ON or OFF bipolar cell.

### Claim 6

A method of quantitative regulation of G protein activation in a cell, wherein the method comprises i) transforming the cell with a vector encoding a bistable opsin wherein the bistable opsin has an inactive and an active state, and transition in both directions between inactive and active states are driven by light absorption; and wherein the bistable opsin in the inactive state is sensitive to a first wavelength of light for transition to an active state, and the bistable opsin in the active state is sensitive to a second wavelength of light for transition to an inactive state, the first and second wavelengths being different; ii) expressing the bistable opsin in the transformed cell; iii) illuminating the transformed cell expressing the bistable opsin with light comprising the first and/or second wavelength, wherein the ratio of the two wavelengths of light regulates the amplitude of a G protein signalling cascade.

### Claim 7 (depends on 6)

A method according to claim 6 wherein the size of the G protein activation response is regulated by the ratio of (light of a first wavelength): (light of a second wavelength) used to illuminate the cell.

### Claim 8

A method of regulating G protein activation in a cell, wherein the method comprises i) transforming the cell with a vector encoding a bistable opsin wherein the bistable opsin has an inactive and an active state, and transition in both directions between inactive and active states are driven by light absorption; and wherein the bistable opsin in the inactive state is sensitive to a first wavelength of light for transition to an active state, and the bistable opsin in the active state is sensitive to a second wavelength of light for transition to an inactive state, the first and second wavelengths being different; ii) expressing the bistable opsin in the transformed cell; iii) illuminating the transformed cell expressing the bistable opsin with light of a first wavelength and/or light of a second wavelength wherein the ratio of the two wavelengths of light regulates a G protein signalling cascade; and wherein the time for G protein response to illumination is between 0.05 and 15 seconds.

### Claim 9 (depends on 8)

A method according to claim 8 wherein the regulation of the G protein comprises quantitative regulation, preferably of a Go protein in a retinal cell, preferably wherein the bistable opsin is lamprey parapinopsin.

### Claim 10

A method for quantitative regulation of the quantity of bistable opsin in an inactive and active state in a cell, wherein transition in both directions between inactive and active states are driven by light absorption; and wherein the bistable opsin in the inactive state is sensitive to a first wavelength of light for transition to an active state, and the bistable opsin in the active state is sensitive to a second wavelength of light for transition to an inactive state, the first and second wavelengths being different; wherein the method comprises illuminating the cell expressing the bistable opsin with light of a first wavelength and/or light of a second wavelength, and wherein the ratio of the two wavelengths of light regulates the amount of bistable opsin in the active state.

### Claim 11 (depends on 10)

A method according to claim 10 wherein the method comprises regulation of the bistable opsin, by exposing the cell to either light of a first wavelength or light of a second wavelength.

### Claim 12 (depends on 10, 11)

A method according to claim 10 or 11 wherein the light is a combination of light of a first wavelength and light of a second wavelength.

### Claim 13 (depends on 10, 11, 12)

A method according to any one of claims 10 to 12 comprising quantitative regulation of the ON-OFF response of a bistable opsin in a retinal cell, preferably wherein the bistable opsin is lamprey parapinopsin.

### Claim 14 (depends on 13)

A method according to claim 13 wherein the retinal cell is an inner retinal cell, preferably a bipolar cell, preferably an ON or OFF bipolar cell.

### Claim 15

A method of restoring vision in a subject by restoring a visual signal transduction response in a retinal cell in a subject, the method comprising i) transforming a retinal cell in the subject with a vector encoding a bistable opsin wherein the bistable opsin has an inactive and an active state, and transition in both directions between inactive and active states are driven by light absorption; and wherein the bistable opsin in the inactive state is sensitive to a first wavelength of light for transition to an active state, and the bistable opsin in the active state is sensitive to a second wavelength of light for transition to an inactive state, the first and second wavelengths being different; ii) expressing the bistable opsin in the transformed cell; iii) illuminating the transformed cell expressing the bistable opsin with light of a first wavelength and/or light of a second wavelength, wherein the ratio of the two wavelengths of light regulates the amplitude of the visual signal transduction response in the cell by regulating the amplitude of G protein activation.

### Claim 16

A method of treatment of retinal degeneration by introducing a visual signal transduction response in a retinal cell in a subject, the method comprising i) transforming a retinal cell in the subject with a vector encoding a bistable opsin wherein the bistable opsin has an inactive and an active state, and transition in both directions between inactive and active states are driven by light absorption; and wherein the bistable opsin in the inactive state is sensitive to a first wavelength of light for transition to an active state, and the bistable opsin in the active state is sensitive to a second wavelength of light for transition to an inactive state, the first and second wavelengths being different; ii) expressing the bistable opsin in the transformed cell; iii) illuminating the transformed cell expressing the bistable opsin with light of a first wavelength and/or light of a second wavelength, wherein the ratio of the two wavelengths of light regulates the amplitude of the visual signal transduction response in the cell by regulating the amplitude of G protein activation.

### Claim 17 (depends on 15, 16)

A method according to claim 15 or 16 wherein the bistable opsin is lamprey parapinopsin.

### Claim 18 (depends on 15, 16, 17)

A method according to any one of claims 15 to 17 wherein the retinal cell is a retinal ganglion cell, or an inner retinal cell, more suitably a bipolar cell, such as an ON or OFF bipolar cell.

### Claim 19 (depends on 15, 16, 17, 18)

A method according to any one of claims 15 to 18 wherein the subject is suffering from, or predisposed to, a disease selected from the group consisting of a retinal dystrophy including a rod dystrophy, a rod-cone dystrophy, a cone-rod dystrophy, a cone dystrophy and a macular dystrophy; another forms of retinal or macular degeneration, an ischaemic conditions, uveitis and any other disease resulting from loss of photoreceptor ability; or Parkinsons disease, Alzheimer's disease, schizophrenia or heart disease.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A method according for the treatment of Parkinsons disease, Alzheimer's disease, schizophrenia and heart disease, wherein the method is as defined in any one of claims 1 to 14.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A method according for the treatment of a disease selected from the group consisting of a retinal dystrophy including a rod dystrophy, a rod-cone dystrophy, a cone-rod dystrophy, a cone dystrophy and a macular dystrophy; another forms of retinal or macular degeneration, an ischaemic conditions, uveitis and any other disease resulting from loss of photoreceptor ability, wherein the method is as defined in any one of claims 1 to 14.

### Claim 22 (depends on 15, 16, 17, 18, 19, 20, 21)

A method according to any one of claims 15 to 21 wherein the regulation of the G protein comprises quantitative regulation.

### Claim 23 (depends on 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

A method according to any one of claims 6 to 22 wherein the G protein is a Go or Gi protein.

### Claim 24 (depends on 6, 7, 8, 9, 10)

A method according to any one of claims 6 to 10, and 15 to 23 wherein the method comprises ON-OFF regulation of the G protein, by exposing the cell to either light of a first wavelength or light of a second wavelength.

### Claim 25

A method according to any one of the preceding claims wherein the first and second wavelength differ by at least 10 nm; and wherein where the light of the first and/or second wavelength is not a single wavelength, it is the wavelengths having the maximum output which differ from each other by at least 10 nm.

### Claim 26

A method according to any one of the preceding claims wherein the light of a first wavelength is from 380-450 nm for transition from the inactive state to active state; and/or the light of the second wavelength is from 450-650 nm for transition from an active to inactive state.

### Claim 27

A method according to any one of the preceding claims wherein the method comprises illuminating the cell with light of a first wavelength or light of a second wavelength for a time period from one or more milli-seconds, up to one or more hours, or during waking hours; preferably wherein the ratio of light of the first wavelength to light of the second wavelength may change one or more times during the time period.

### Claim 28 (depends on 27)

A method according to claim 27 wherein the ratio changes every millisecond.

### Claim 29

A nucleic acid vector comprising a nucleic acid encoding i) a bistable opsin which has an inactive and an active state, and transition in both directions between inactive and active states are driven by light absorption; and wherein the bistable opsin in the inactive state is sensitive to a first wavelength of light for transition to an active state, and the bistable opsin in the active state is sensitive to a second wavelength of light for transition to an inactive state, the first and second wavelengths being different; and ii) a promoter which is specific for expression in an inner retinal cell.

### Claim 30 (depends on 29)

A nucleic acid vector according to claim 29 wherein the promoter is specific for bipolar cells, specifically ON bipolar cells.

### Claim 31 (depends on 29, 30)

A nucleic acid vector according to claim 29 or 30 wherein the promoter is grm6, a fragment thereof or a derivative thereof, and preferably is a synthetic promoter derived from a naturally occurring grm6 promoter.

### Claim 32 (depends on 29, 30, 31)

A nucleic acid vector according to any one of claims 29 to 31 wherein the vector is a viral vector, preferably AAV.

### Claim 33 (depends on 29, 30, 31, 32)

A kit comprising i) a nucleic acid vector comprising a nucleic acid encoding a bistable opsin which has an inactive and an active state, and transition in both directions between inactive and active states are driven by light absorption; and wherein the bistable opsin in the inactive state is sensitive to a first wavelength of light for transition to an active state, and the bistable opsin in the active state is sensitive to a second wavelength of light for transition to an inactive state, the first and second wavelengths being different, and ii) a light source which emits light in the first wavelength and/or light in the second wavelength; preferably wherein the vector is as defined in any one of claims 29 to 32.

### Claim 34 (depends on 29, 30, 31, 32)

A nucleic acid vector or a kit according to any one of claims 29 to 32 for use in the treatment of Parkinsons disease, Alzheimer's disease, schizophrenia and heart disease; or for use in the treatment of a disease selected from the group consisting of a retinal dystrophy including a rod dystrophy, a rod-cone dystrophy, a cone-rod dystrophy, a cone dystrophy and a macular dystrophy; another forms of retinal or macular degeneration, an ischaemic conditions, uveitis and any other disease resulting from loss of photoreceptor ability.

### Claim 35

A method, vector or kit according to any one of the preceding claims wherein the bistable opsin is a parapinopsin, for example lamprey parapinopsin, preferably encoded by the sequence of Genbank AB116380.1 or a variant or derivative thereof.

### Claim 36

A method, vector or kit according to any one of the preceding claims wherein the sequence encoding a bistable opsin is provided in a viral vector, preferably an AAV vector.
